No Medications Are FDA-Approved for Internet Gaming Disorder
There are currently no medications with formal regulatory approval (FDA or otherwise) specifically indicated for Internet Gaming Disorder (IGD). The evidence base consists entirely of off-label use of various psychotropic medications, with preliminary data suggesting potential benefit but lacking the rigor needed for definitive recommendations.
Current State of Pharmacological Evidence
Most Studied Medications (Off-Label Use Only)
The available research on pharmacological treatment of IGD is limited to small studies, primarily from South Korea, with significant methodological limitations 1:
- Bupropion - Most commonly studied antidepressant, showing symptom reductions of 15.4% to 51.4% in various trials 1
- Selective Serotonin Reuptake Inhibitors (SSRIs) - Including escitalopram, showing benefits particularly when IGD is comorbid with major depressive disorder 2
- Methylphenidate - Studied in patients with comorbid ADHD and IGD, but notably did not show direct impact on IGD symptom reduction despite treating ADHD symptoms 3
- N-acetylcysteine - Case reports suggest potential utility, theoretically targeting glutamatergic dysfunction similar to other addictive disorders 4
Critical Limitations of Current Evidence
The pharmacological evidence base for IGD has severe constraints 1:
- Sample bias: 98.6% of participants were male, all from South Korea - limiting generalizability
- Quality concerns: Only 4 of 12 clinical trials had low risk of bias
- No double-blind RCTs: Most studies lack rigorous randomized controlled designs 2
- Comorbidity confounding: Studies often fail to control for psychiatric comorbidities, making it unclear whether medications treat IGD itself or associated conditions 1, 2
Recommended Clinical Approach
Primary Treatment Strategy
Cognitive Behavioral Therapy (CBT) should be the first-line treatment, as it has the most extensive research support with several randomized controlled trials demonstrating efficacy 5, 6. Meta-analytic evidence shows CBT produces large effect sizes for GD symptom reduction (Hedges' g = 1.38) with sustained benefits at 90-day follow-up 6.
When to Consider Pharmacotherapy
Medications should be considered only as adjunctive treatment in these specific scenarios:
- Comorbid major depressive disorder: Consider SSRIs (escitalopram) as they address both depression and may reduce IGD symptoms 2
- Comorbid ADHD: Methylphenidate treats ADHD but does not directly reduce IGD symptoms; psychological interventions remain necessary for the gaming disorder itself 3
- Treatment-resistant cases: After failure of evidence-based psychological interventions, consider bupropion or SSRIs off-label, with informed consent about limited evidence 1
Critical Caveats
- Screen for comorbidities: IGD has high rates of depression (30%), anxiety, ADHD, and substance use disorders that require independent assessment and treatment 5
- Avoid monotherapy: Pharmacological treatment alone is insufficient; always combine with psychological interventions 2, 6
- Monitor closely: Given the lack of established dosing protocols and limited safety data specific to IGD, frequent monitoring is essential 1
Research Gaps Requiring Urgent Attention
The National UK Research Network for Behavioural Addictions identifies the need for randomized controlled trials on pharmacotherapy for gambling disorder (a related behavioral addiction), noting that "there has been little research on what predicts who will benefit from these options" and "virtually no data regarding how much therapy is ideally needed" 5. These same gaps apply to IGD, where larger, well-designed RCTs are needed to establish effective treatments 2, 6.
The current evidence suggests that psychological interventions, particularly CBT, should remain the cornerstone of treatment, with pharmacotherapy reserved for addressing specific comorbidities or as adjunctive treatment in refractory cases 6.